170 related articles for article (PubMed ID: 36961000)
1. Feasibility of [
Bae SW; Wang J; Georgiou DK; Wen X; Cohen AS; Geng L; Tantawy MN; Manning HC
Tomography; 2023 Feb; 9(2):497-508. PubMed ID: 36961000
[TBL] [Abstract][Full Text] [Related]
2. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K
Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621
[TBL] [Abstract][Full Text] [Related]
3. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
4. Utility of [
Kavanaugh G; Williams J; Morris AS; Nickels ML; Walker R; Koglin N; Stephens AW; Washington MK; Geevarghese SK; Liu Q; Ayers D; Shyr Y; Manning HC
Mol Imaging Biol; 2016 Dec; 18(6):924-934. PubMed ID: 27677886
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of [
Colovic M; Yang H; Southcott L; Merkens H; Colpo N; Bénard F; Schaffer P
J Nucl Med; 2023 Aug; 64(8):1314-1321. PubMed ID: 37116917
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
7. [
Hoehne A; James ML; Alam IS; Ronald JA; Schneider B; D'Souza A; Witney TH; Andrews LE; Cropper HC; Behera D; Gowrishankar G; Ding Z; Wyss-Coray T; Chin FT; Biswal S; Gambhir SS
J Neuroinflammation; 2018 Feb; 15(1):55. PubMed ID: 29471880
[TBL] [Abstract][Full Text] [Related]
8. Initial evaluation of (4S)-4-(3-[
Park SY; Mosci C; Kumar M; Wardak M; Koglin N; Bullich S; Mueller A; Berndt M; Stephens AW; Chin FT; Gambhir SS; Mittra ES
EJNMMI Res; 2020 Aug; 10(1):100. PubMed ID: 32857284
[TBL] [Abstract][Full Text] [Related]
9. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
10. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
11. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer.
Baek S; Choi CM; Ahn SH; Lee JW; Gong G; Ryu JS; Oh SJ; Bacher-Stier C; Fels L; Koglin N; Hultsch C; Schatz CA; Dinkelborg LM; Mittra ES; Gambhir SS; Moon DH
Clin Cancer Res; 2012 Oct; 18(19):5427-37. PubMed ID: 22893629
[TBL] [Abstract][Full Text] [Related]
12. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
13. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
15. Radiotracer stereochemistry affects substrate affinity and kinetics for improved imaging of system x
Greenwood HE; Edwards R; Koglin N; Berndt M; Baark F; Kim J; Firth G; Khalil E; Mueller A; Witney TH
Theranostics; 2022; 12(4):1921-1936. PubMed ID: 35198080
[TBL] [Abstract][Full Text] [Related]
16. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of (4S)-4-(3-
Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754
[TBL] [Abstract][Full Text] [Related]
18. Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography.
Greenwood HE; McCormick PN; Gendron T; Glaser M; Pereira R; Maddocks ODK; Sander K; Zhang T; Koglin N; Lythgoe MF; Årstad E; Hochhauser D; Witney TH
Clin Cancer Res; 2019 Apr; 25(8):2471-2482. PubMed ID: 30651275
[TBL] [Abstract][Full Text] [Related]
19. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Tumor Redox Status through (
McCormick PN; Greenwood HE; Glaser M; Maddocks ODK; Gendron T; Sander K; Gowrishankar G; Hoehne A; Zhang T; Shuhendler AJ; Lewis DY; Berndt M; Koglin N; Lythgoe MF; Gambhir SS; Årstad E; Witney TH
Cancer Res; 2019 Feb; 79(4):853-863. PubMed ID: 30401715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
